Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.8B | $19.9B | $18.9B | $16.8B | $19.4B | $27.8B | $32.0B | $34.1B | $40.6B | $45.4B |
| Revenue growth | — | 11.8% | -5.0% | -10.9% | 15.4% | 43.0% | 15.1% | 6.6% | 19.3% | 11.7% |
| Gross profit | $1.73B | $1.81B | $2.52B | $2.30B | $2.48B | — | — | — | — | — |
| Gross margin | 9.7% | 9.1% | 13.3% | 13.7% | 12.8% | — | — | — | — | — |
| Operating income | $306M | -$555M | $1.13B | $1.04B | $1.08B | $1.02B | $1.17B | $1.57B | $1.71B | $781M |
| Operating margin | 1.7% | -2.8% | 6.0% | 6.2% | 5.6% | 3.7% | 3.7% | 4.6% | 4.2% | 1.7% |
| Net income | $52.0M | -$512M | $707M | $737M | $673M | $659M | $792M | $1.09B | $1.18B | $472M |
| Net margin | 0.3% | -2.6% | 3.7% | 4.4% | 3.5% | 2.4% | 2.5% | 3.2% | 2.9% | 1.0% |
| EPS (diluted) | $0.92 | -$9.07 | $10.61 | $11.47 | $11.23 | $11.25 | $13.55 | $18.77 | $20.42 | $8.92 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $673M | $804M | -$314M | $434M | $1.90B | $2.12B | $773M | $1.66B | $644M | -$535M |
| Capital expenditures | $176M | $86.0M | $30.0M | $57.0M | $74.0M | $77.0M | $91.0M | $84.0M | $100M | $101M |
| Free cash flow | $497M | $718M | -$344M | $377M | $1.82B | $2.04B | $682M | $1.58B | $544M | -$636M |
| Share buybacks | — | $0.00 | $0.00 | $47.0M | $606M | $128M | $400M | $0.00 | $1.00B | $1.00B |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.82B | $3.19B | $2.83B | $2.45B | $4.15B | $4.44B | $4.01B | $4.85B | $4.66B | $4.25B |
| Total assets | $7.45B | $8.47B | $7.15B | $6.79B | $9.53B | $12.2B | $12.3B | $14.9B | $15.6B | $15.6B |
| Total liabilities | $5.80B | $7.13B | $5.51B | $4.83B | $7.44B | $9.58B | $9.35B | $10.7B | $11.1B | $11.5B |
| Long-term debt | $975M | $1.32B | $1.02B | $1.24B | $2.13B | $2.17B | $2.18B | $2.18B | $2.92B | $3.77B |
| Shareholders' equity | $1.65B | $1.34B | $1.65B | $1.96B | $2.10B | $2.63B | $2.96B | $4.21B | $4.50B | $4.07B |
| Retained earnings | $810M | $298M | $1.01B | $1.78B | $1.86B | $2.40B | $2.80B | $3.89B | $4.09B | $3.60B |
| Shares (wtd avg diluted) | 56.2M | 56.4M | 66.6M | 64.2M | 59.9M | 58.6M | 58.5M | 58.1M | 57.7M | 52.9M |
Every figure is extracted from MOLINA HEALTHCARE, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.